Navigation Links
Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
Date:11/19/2008

(11,517,459) Interest income 433,646 1,032,800 941,933 2,150,031 Interest expense (929,018) (1,402,789) (2,090,668) (2,799,996) Gain on early extinguishment of debt 4,612,845 -- 4,612,845 -- Other (expense), net (162,494) (83,664) (145,260) (41,098) Income (loss) before income tax 8,471,506 (4,061,998) 10,617,531 (12,208,522) Income tax expense 121,304 15,342 214,528 32,281 Net income (loss) $8,350,202 $(4,077,340) $10,403,003 $(12,240,803) Basic income (loss) per share $0.31 $(0.15) $0.39 $(0.46) Diluted income (loss) per share $0.14 $(0.15) $ 0.23 $(0.46) Shares used in computing basic income (loss) per share 26,680,551 26,529,485 26,550,667 26,441,601 Shares used in computing diluted income (loss) per share 27,516,723 26,529,485 27,632,656 26,441,601 RECONCILIATION OF NON-GAAP FINANCIAL MEASURE (Unaudited) For the Thirteen For the Twenty-Six Weeks Ended Weeks Ended October 24, 2008 October 24, 2008 Net Income $8,350,202 $10,403,003 Gain on early extinguishment of debt adjusted for tax impact, net (4,614,251) (4,617,062) Adjusted Net Income $3,735,951 $5,785,941
'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
2. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
3. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
4. Cyberonics to Present at UBS Global Life Sciences Conference
5. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
7. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
8. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
11. Cyberonics Licenses Obesity-Related Patents
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4